Genetic Technologies Limited (GENE)
USD 0.77
(0.0%)
USD 0.77
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -12.01 Million AUD | -2.27% |
| 2023 | -11.75 Million AUD | -64.79% |
| 2022 | -7.13 Million AUD | 1.07% |
| 2021 | -7.2 Million AUD | -14.34% |
| 2020 | -6.3 Million AUD | 7.74% |
| 2019 | -6.83 Million AUD | -25.06% |
| 2018 | -5.46 Million AUD | 34.98% |
| 2017 | -8.4 Million AUD | 0.65% |
| 2016 | -8.45 Million AUD | 3.99% |
| 2015 | -8.81 Million AUD | 12.99% |
| 2014 | -10.12 Million AUD | -8.3% |
| 2013 | -9.34 Million AUD | -76.82% |
| 2012 | -5.28 Million AUD | -681.05% |
| 2011 | 910 Thousand AUD | 109.74% |
| 2010 | -9.34 Million AUD | 3.83% |
| 2009 | -9.71 Million AUD | -78.02% |
| 2008 | -5.45 Million AUD | -227.66% |
| 2007 | -1.66 Million AUD | 69.26% |
| 2006 | -5.41 Million AUD | 28.07% |
| 2005 | -7.53 Million AUD | -9.32% |
| 2004 | -6.88 Million AUD | -59.28% |
| 2003 | -4.32 Million AUD | 50.99% |
| 2002 | -8.82 Million AUD | -160.28% |
| 2001 | -3.39 Million AUD | -38.97% |
| 2000 | -2.43 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -3.2 Million AUD | 48.98% |
| 2024 FY | -12.01 Million AUD | -2.27% |
| 2024 Q2 | -6.41 Million AUD | 0.0% |
| 2024 Q3 | -2.79 Million AUD | 56.4% |
| 2024 Q4 | -2.79 Million AUD | 0.0% |
| 2023 FY | -11.75 Million AUD | -64.79% |
| 2023 Q1 | -2.73 Million AUD | 15.99% |
| 2023 Q3 | -3.14 Million AUD | 42.4% |
| 2023 Q4 | -6.29 Million AUD | -100.0% |
| 2023 Q2 | -5.46 Million AUD | -100.0% |
| 2022 Q3 | -1.62 Million AUD | 58.14% |
| 2022 Q2 | -3.88 Million AUD | -100.0% |
| 2022 Q4 | -3.24 Million AUD | -100.0% |
| 2022 FY | -7.13 Million AUD | 1.07% |
| 2022 Q1 | -1.94 Million AUD | 46.13% |
| 2021 Q2 | -3.47 Million AUD | -100.0% |
| 2021 Q1 | -1.73 Million AUD | 49.65% |
| 2021 FY | -7.2 Million AUD | -14.34% |
| 2021 Q4 | -3.6 Million USD | -100.0% |
| 2021 Q3 | -1.8 Million AUD | 48.17% |
| 2020 Q4 | -3.45 Million AUD | -89.26% |
| 2020 FY | -6.3 Million AUD | 7.74% |
| 2020 Q2 | -2.64 Million AUD | -100.0% |
| 2020 Q3 | -1.82 Million AUD | 31.13% |
| 2020 Q1 | -1.32 Million AUD | 59.91% |
| 2019 Q1 | -1.56 Million AUD | -44.31% |
| 2019 FY | -6.83 Million AUD | -25.06% |
| 2019 Q2 | -1.56 Million AUD | 0.0% |
| 2019 Q3 | -1.65 Million AUD | -5.73% |
| 2019 Q4 | -3.3 Million USD | -100.0% |
| 2018 Q4 | -1.08 Million AUD | 0.0% |
| 2018 FY | -5.46 Million AUD | 34.98% |
| 2018 Q2 | -1.64 Million AUD | 0.0% |
| 2018 Q1 | -1.64 Million AUD | 23.82% |
| 2018 Q3 | -1.08 Million AUD | 34.4% |
| 2017 Q4 | -2.16 Million AUD | 0.0% |
| 2017 Q3 | -2.16 Million AUD | -6.36% |
| 2017 Q2 | -2.03 Million AUD | 0.0% |
| 2017 Q1 | -2.03 Million AUD | 0.97% |
| 2017 FY | -8.4 Million AUD | 0.65% |
| 2016 Q4 | -2.05 Million AUD | 0.0% |
| 2016 Q2 | -2.17 Million AUD | 0.0% |
| 2016 Q1 | -2.17 Million AUD | -9.25% |
| 2016 Q3 | -2.05 Million AUD | 5.39% |
| 2016 FY | -8.45 Million AUD | 3.99% |
| 2015 FY | -8.81 Million AUD | 12.99% |
| 2015 Q4 | -1.98 Million AUD | 0.0% |
| 2015 Q3 | -1.98 Million AUD | 17.65% |
| 2015 Q2 | -2.41 Million AUD | 0.0% |
| 2015 Q1 | -2.41 Million AUD | 3.87% |
| 2014 Q4 | -2.51 Million AUD | 0.0% |
| 2014 FY | -10.12 Million AUD | -8.3% |
| 2014 Q2 | -2.54 Million AUD | 0.0% |
| 2014 Q1 | -2.54 Million AUD | 8.68% |
| 2014 Q3 | -2.51 Million AUD | 1.43% |
| 2013 Q1 | -1.85 Million AUD | 0.0% |
| 2013 FY | -9.34 Million AUD | -76.82% |
| 2013 Q3 | -2.79 Million AUD | -50.3% |
| 2013 Q2 | -1.85 Million AUD | 0.0% |
| 2013 Q4 | -2.79 Million AUD | 0.0% |
| 2012 FY | -5.28 Million AUD | -681.05% |
| 2012 Q2 | - AUD | 0.0% |
| 2012 Q3 | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 Q2 | - AUD | 0.0% |
| 2011 FY | 910 Thousand AUD | 109.74% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | -9.34 Million AUD | 3.83% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | -9.71 Million AUD | -78.02% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | -5.45 Million AUD | -227.66% |
| 2008 Q1 | -226.91 Thousand AUD | -119.92% |
| 2008 Q2 | -226.83 Thousand AUD | 0.04% |
| 2008 Q4 | -2.5 Million AUD | 0.01% |
| 2008 Q3 | -2.5 Million AUD | -1002.98% |
| 2007 Q3 | 1.39 Million AUD | 152.33% |
| 2007 Q4 | 1.13 Million AUD | -18.13% |
| 2007 FY | -1.66 Million AUD | 69.26% |
| 2007 Q2 | -2.65 Million AUD | 25.26% |
| 2007 Q1 | -3.55 Million AUD | -196.57% |
| 2006 Q3 | -1.4 Million AUD | 8.62% |
| 2006 Q4 | -1.19 Million AUD | 14.72% |
| 2006 Q1 | -1.53 Million AUD | -215.27% |
| 2006 FY | -5.41 Million AUD | 28.07% |
| 2006 Q2 | -1.53 Million AUD | -0.01% |
| 2005 FY | -7.53 Million AUD | -9.32% |
| 2005 Q4 | -488.07 Thousand AUD | 92.5% |
| 2005 Q1 | -283.92 Thousand AUD | 0.0% |
| 2005 Q2 | -264.78 Thousand AUD | 6.74% |
| 2005 Q3 | -6.5 Million AUD | -2358.14% |
| 2004 FY | -6.88 Million AUD | -59.28% |
| 2003 FY | -4.32 Million AUD | 50.99% |
| 2002 FY | -8.82 Million AUD | -160.28% |
| 2001 FY | -3.39 Million AUD | -38.97% |
| 2000 FY | -2.43 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bionano Genomics, Inc. | -232.49 Million USD | 94.831% |
| iSpecimen Inc. | -11.09 Million USD | -8.268% |
| Prenetics Global Limited | -62.72 Million USD | 80.841% |
| OpGen, Inc. | -32.66 Million USD | 63.215% |
| Exact Sciences Corporation | -204.14 Million USD | 94.114% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -676.306% |
| CareDx, Inc | -190.28 Million USD | 93.685% |
| Exagen Inc. | -23.68 Million USD | 49.271% |
| Inotiv, Inc. | -105.14 Million USD | 88.57% |
| Guardant Health, Inc. | -479.44 Million USD | 97.494% |
| Biodesix, Inc. | -52.14 Million USD | 76.955% |
| BioNexus Gene Lab Corp. | -2.62 Million USD | -357.095% |
| Precipio, Inc. | -5.85 Million USD | -105.317% |
| Aspira Women's Health Inc. | -16.69 Million USD | 27.997% |
| Standard BioTools Inc. | -74.65 Million USD | 83.903% |
| 23andMe Holding Co. | -666.7 Million USD | 98.198% |
| Castle Biosciences, Inc. | -57.46 Million USD | 79.088% |
| Personalis, Inc. | -108.29 Million USD | 88.903% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 86.418% |
| Applied DNA Sciences, Inc. | -9.94 Million USD | -20.812% |
| T2 Biosystems, Inc. | -50.07 Million USD | 76.003% |
| Neogen Corporation | -9.42 Million USD | -27.558% |
| Natera, Inc. | -434.8 Million USD | 97.236% |
| Myriad Genetics, Inc. | -112 Million USD | 89.27% |
| ICON Public Limited Company | 612.33 Million USD | 101.963% |
| NeoGenomics, Inc. | -87.96 Million USD | 86.339% |
| Star Equity Holdings, Inc. | -1.54 Million USD | -676.306% |
| IDEXX Laboratories, Inc. | 845.04 Million USD | 101.422% |
| RadNet, Inc. | 3.04 Million USD | 494.784% |
| MDxHealth SA | -43.1 Million USD | 72.118% |
| Check-Cap Ltd. | -17.56 Million USD | 31.596% |
| Twist Bioscience Corporation | -208.72 Million USD | 94.243% |
| Psychemedics Corporation | -4.15 Million USD | -189.293% |
| Fulgent Genetics, Inc. | -167.82 Million USD | 92.839% |
| Sera Prognostics, Inc. | -36.24 Million USD | 66.842% |
| OPKO Health, Inc. | -188.86 Million USD | 93.637% |
| Illumina, Inc. | -1.16 Billion USD | 98.965% |
| DarioHealth Corp. | -59.42 Million USD | 79.778% |
| ENDRA Life Sciences Inc. | -10.06 Million USD | -19.452% |
| Medpace Holdings, Inc. | 282.81 Million USD | 104.249% |
| Prenetics Global Limited | -62.72 Million USD | 80.841% |
| Intelligent Bio Solutions Inc. | -10.15 Million USD | -18.317% |
| Mainz Biomed B.V. | -26.29 Million USD | 54.3% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -51.407% |
| Trinity Biotech plc | -24.01 Million USD | 49.966% |
| Neuronetics, Inc. | -30.18 Million USD | 60.193% |
| Sotera Health Company | 51.37 Million USD | 123.391% |
| bioAffinity Technologies, Inc. | -7.93 Million USD | -51.407% |